<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00131248</url>
  </required_header>
  <id_info>
    <org_study_id>GERD</org_study_id>
    <nct_id>NCT00131248</nct_id>
  </id_info>
  <brief_title>Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants</brief_title>
  <official_title>Cross-over Trial of Medical Treatment for GERD in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <brief_summary>
    <textblock>
      Study Question: In premature infants with apnea and/or bradycardia attributed to
      gastroesophageal reflux disease (GERD), does treatment with medications (acid blockers and
      motility agents), compared to placebo, reduce the frequency of apnea and bradycardia?

      Background: Many clinicians believe that apnea and bradycardia in preterm infants may be
      caused by gastroesophageal reflux (GER), however, studies have failed to demonstrate even a
      temporal association between episodes of GER and apnea. There have been no prospective
      randomized trials of treatment for GERD in preterm infants with apnea or other symptoms
      attributed to GER.

      Methods: A randomized, cross-over study will be performed. This cross-over design will
      provide the patient's clinician with unbiased information about the patient's response to
      treatment. The clinician can use this information in deciding whether or not to continue
      treatment after the two-week study period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Question: In premature infants with apnea and/or bradycardia attributed to GERD, does
      treatment with H2 blockers and prokinetic agents, compared to placebo, reduce the frequency
      of apnea and bradycardia?

      Background: The incidence of gastroesophageal reflux (GER) has been reported in as many as
      50% of healthy term infants and 63% of preterm infants. Anecdotal observations of apnea and
      bradycardia clustered around feedings or with an episode of vomiting have suggested to
      clinicians that apnea and bradycardia in preterm infants may be caused by reflux, however,
      studies have failed to demonstrate even a temporal association between episodes of GER and
      apnea. One retrospective study concluded that anti-reflux medications did not reduce the
      frequency of apnea in premature infants. There have been no prospective randomized trials of
      treatment for GERD in preterm infants with apnea or other symptoms attributed to GER. Despite
      the lack of evidence supporting a causal relationship between GER and respiratory problems in
      preterm infants and the lack of data regarding the efficacy or safety of the treatments for
      GERD, many clinicians continue to believe that GER causes respiratory symptoms in preterm
      infants and these infants are commonly treated with medications for GERD.

      Specific aims: To determine whether medications for GER are effective in reducing respiratory
      symptoms attributed to GER.

      Methods: A randomized, controlled masked cross-over study will be performed. The cross-over
      design will prevent evaluation of long-term outcomes but will increase the power to evaluate
      short-term outcomes by using the patient as his/her own control. This cross-over design will
      also provide the patient's clinician with unbiased information about the patient's response
      to treatment. The clinician can use this information in deciding whether or not to continue
      treatment after the two-week study period. This approach for making therapeutic decisions in
      individual patients has been described as an &quot;N of 1&quot; trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bradycardia Episodes/Day</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Anti-reflux Medications, then Placebo (group 1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3-day course of anti-reflux medications, followed by 7-day course placebo, followed by 4-day course anti-reflux medications.
All study medication administered via nipple or orogastric (OG) tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then Anti-reflux Medications</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3-day course placebo, followed by 7-day course anti-reflux medication, followed by 4-day course placebo.
All study medication administered via nipple or OG tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metaclopramide</intervention_name>
    <arm_group_label>Anti-reflux Medications, then Placebo (group 1)</arm_group_label>
    <arm_group_label>Placebo, then Anti-reflux Medications</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranitidine</intervention_name>
    <arm_group_label>Anti-reflux Medications, then Placebo (group 1)</arm_group_label>
    <arm_group_label>Placebo, then Anti-reflux Medications</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Anti-reflux Medications, then Placebo (group 1)</arm_group_label>
    <arm_group_label>Placebo, then Anti-reflux Medications</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premature infants &lt; 37 weeks gestation at birth; currently less than 44 weeks
             postmenstrual age.

          -  Not currently receiving mechanical ventilation

          -  Clinical diagnosis of GER and apnea/bradycardia suspected by the clinicians to be
             related to the GER. (Supporting diagnostic test information, such as upper
             gastrointestinal series [UGI] studies and pH probes will be recorded but not required
             for study enrollment.)

          -  Attending physician plan to begin anti-reflux medications

          -  Infants may be included in the study if they are on continuous positive airway
             pressure (CPAP) or methylxanthines for treatment of apnea only if the clinicians are
             willing to maintain the same regimen for the two-week duration of the study.

          -  Stable feeding regimen

        Exclusion Criteria:

          -  History of congenital neurological defect

          -  Imminent discharge (within 2 weeks)

          -  Parent refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen A Kennedy, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Hermann Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wheatley E, Kennedy KA. Cross-over trial of treatment for bradycardia attributed to gastroesophageal reflux in preterm infants. J Pediatr. 2009 Oct;155(4):516-21. doi: 10.1016/j.jpeds.2009.03.044. Epub 2009 Jun 21.</citation>
    <PMID>19540518</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2005</study_first_submitted>
  <study_first_submitted_qc>August 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2005</study_first_posted>
  <results_first_submitted>November 23, 2009</results_first_submitted>
  <results_first_submitted_qc>December 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 15, 2014</results_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Kathleen Kennedy</investigator_full_name>
    <investigator_title>Professor - Pediatrics-Neonatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
    <mesh_term>Ranitidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>participants = premature infants, &lt;36 weeks gestation at birth, recruited from NICU at a hospital in Houston, Texas,USA, between 2004-2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Medications, Placebo, Medications (Group 1)</title>
          <description>3-day course of anti-reflux medications, followed by 7-day course placebo, followed by 4-day course anti-reflux medications.
All study medication administered via nipple or OG tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Medications, Placebo (Group 2)</title>
          <description>received 3-day course placebo, followed by 7-day course anti-reflux medication, followed by 4-day course placebo.
All study medication administered via nipple or OG tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention 1 (3-day Course)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (24 Hour)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 2 (7-day Course)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout 2 (24 Hours)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 3 (4-day Course)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>18 participants initially enrolled; 1 withdrew, leaving 17 participants analyzed.</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.1" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bradycardia Episodes/Day</title>
        <time_frame>7 days</time_frame>
        <population>18 participants originally enrolled, 1 withdrew, leaving 17 participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Medications</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Bradycardia Episodes/Day</title>
          <population>18 participants originally enrolled, 1 withdrew, leaving 17 participants analyzed.</population>
          <units>episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="3.1"/>
                    <measurement group_id="O2" value="3.6" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety population include only those who received study intervention.</desc>
      <group_list>
        <group group_id="E1">
          <title>Medications</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathleen A. Kennedy, MD, MPH</name_or_title>
      <organization>UT Houston Medical School</organization>
      <phone>713 500-6708</phone>
      <email>kathleen.a.kennedy@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

